2 completed, 1 active not recruiting, 1 withdrawn. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 1, Withdrawn 1 |
Follow ripretinib: new trials by email Literature Review of ripretinib trials Research Report on ripretinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies Inlexisertib, Ripretinib - GIST | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 94 | 2023-09-28 | 2026-10-20 |
| Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) Ripretinib, binimetinib - Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | Withdrawn | Deciphera Pharmaceuticals, LLC | 2021-11-01 | 2022-01-05 | |
| A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib Ripretinib, Sunitinib - Gastrointestinal Stromal Tumor(GIST) | Phase 2 | Completed | Zai Lab (Shanghai) Co., Ltd. | 108 | 2020-11-25 | 2026-04-03 |
| A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) DCC-2618 - Gastrointestinal Stromal Tumors | Phase 2 | Completed | Zai Lab (Shanghai) Co., Ltd. | 39 | 2020-04-23 | 2025-03-03 |
Gastrointestinal Stromal Tumors (4)
Deciphera Pharmaceuticals, LLC (2) · Zai Lab (Shanghai) Co., Ltd. (2)
China (2) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Portugal (1) · Spain (1) · Switzerland (1) · United States (1)
Zai Lab (1)